A London biotech startup has raised $3 million to build a model of how cancer works. Not a model of a single protein or pathway, but a simulation of the entire tumor microenvironment, including immune cells and surrounding tissue. The goal is to use that simulation to find the right combination of existing drugs to attack complex diseases, starting with cancer [Big Picture Bio, September 2026].
Founded in 2026, Big Picture Bio emerged from stealth last September with a £2.2 million (approximately $3 million) war chest. The capital is a mix of a £1.5 million pre-seed equity round and a £700,000 non-dilutive grant from Innovate UK [Big Picture Bio, September 2026]. The company’s bet is that a more holistic, AI-driven view of disease biology can outmaneuver the problem of treatment resistance, a multi-billion dollar dead end for pharmaceutical R&D.
The Wedge: From Simulation to Wet Lab
The company’s platform, described as an AI-powered "world model," is designed to map interactions across disease sites and patient subgroups [Big Picture Bio, September 2026]. Its initial focus is identifying and optimizing combination therapies, determining not just which drugs to use together but potentially in what sequence [The Founder Gazette, September 2026]. This is a step beyond many AI drug discovery tools that focus on novel molecule generation. Big Picture Bio is starting with the drugs already on the shelf.
Its differentiation rests on a closed-loop approach. The AI generates predictions for synergistic drug combinations, which are then slated for wet-lab validation. The Innovate UK grant is specifically earmarked to move the company’s first designed combinations from in silico work into the lab [Big Picture Bio, September 2026]. Early, unverified claims suggest the platform has been validated against real-world clinical outcomes and even predicted the failure of a recent late-stage trial [Technology Networks, International Biopharmaceutical Industry].
The Team From Deep Science Ventures
The founding duo, Dr. Kerstin Papenfuss (CEO) and Dr. Mark Hammond (CTO), both hail from Deep Science Ventures, a venture builder known for spinning out deep tech and life science companies [Big Picture Bio, September 2026]. Their public backgrounds are described as spanning drug discovery, venture creation, and AI-enabled scientific discovery, though specific prior operational roles are not detailed in available materials.
They have assembled an advisory board with ties to established industry players, including executives associated with AstraZeneca, Exscientia, and PhoreMost [N24, September 2026]. This network will be critical for a startup whose likely customers are large pharmaceutical and biotechnology companies seeking to de-risk their combination therapy pipelines.
The Funding Breakdown
The pre-seed round was co-led by Kadmos Capital and Exceptional Ventures, with participation from Gloucester Ventures and angel investor John White [Big Picture Bio, September 2026]. The structure of the raise is notable: nearly a third of the total announced capital is non-dilutive grant funding. This extends the startup’s runway specifically for its costly validation work without further equity sacrifice.
| Date | Round Type | Amount | Lead Investor(s) |
|---|---|---|---|
| September 2026 | Pre-Seed Equity | £1.5M (~$2M) | Kadmos Capital, Exceptional Ventures |
| September 2026 | Grant | £0.7M (~$0.95M) | Innovate UK Investor Partnerships Programme |
| Total | £2.2M (~$3M) |
The Road to a First Deal
For all its technical ambition, Big Picture Bio’s commercial path is the classic biotech services climb. The company must convert its simulated predictions into validated biological data that a pharma partner would pay for. Its website references structured partnerships with AbbVie, the Cystic Fibrosis Foundation, and Cancer Research UK, though the scope and commercial nature of these relationships are not specified [bigpicturebio.com].
The next twelve months will be about proving the model in the physical world. The capital is intended to fund the wet-lab validation of its first AI-designed combinations [Big Picture Bio, September 2026]. Success here would provide the tangible proof points needed to secure a flagship partnership or a larger Series A. The risks are familiar but formidable.
- Technical Validation. The core hypothesis,that a proprietary "world model" can reliably predict clinical outcomes,remains unproven at scale. Wet-lab results must convincingly demonstrate predictive power beyond existing methods.
- Commercial Adoption. The sales cycle to large pharma is long and relationship-driven. The startup must navigate from research collaboration to a revenue-generating deal.
- Competitive Landscape. While no direct competitors are named in sources, the field of AI for drug discovery is crowded with well-funded players also chasing pharma dollars.
The $2 million equity check from Kadmos Capital and Exceptional Ventures, supplemented by the Innovate UK grant, buys the team time to tackle the first risk head-on. If their wet-lab data hits, the question for 2027 won’t be about building a better simulation. It will be about which pharma giant writes the first check to use it.
Sources
- [Big Picture Bio, September 2026] Press Release 17 September 2026 | https://bigpicturebio.com/press/big-picture-bio-launch-17-september-2026.pdf
- [The Founder Gazette, September 2026] Big Picture Bio leaves stealth with £2.2m, £700k of it non-dilutive | https://www.thefoundergazette.com/stories/big-picture-bio-leaves-stealth-with-2-2m-700k-of-it-non-dilu
- [N24, September 2026] Big Picture Bio Secures €2.55M for AI Cancer Therapy | https://n24.com.tr/en/health/big-picture-bio-secures-255m-for-ai-cancer-therapy-791
- [Technology Networks] The company's platform has been validated against real-world clinical outcomes presented at ASCO | https://www.technologynetworks.com
- [International Biopharmaceutical Industry] The company's platform correctly predicted the failure of Regeneron's recent fianlimab trial | https://international-biopharmaceutical-industry.com
- [bigpicturebio.com] Company Page | https://bigpicturebio.com/